Rare Earths Americas Raises $63 Million in IPO at High End of Range
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Source: renaissancecapital
- Successful Fundraising: Rare Earths Americas raised $63 million by offering 3.3 million shares at $19 each, achieving the high end of the $17 to $19 range, indicating strong market confidence in its rare earth projects.
- Market Valuation Increase: The pricing gives the company a fully diluted market value of $399 million, an 8% increase from original terms, reflecting investor recognition of ongoing demand for rare earth resources and the company's future potential.
- Project Portfolio Overview: The company has three key projects in the US and Brazil focused on heavy rare earth elements such as neodymium-praseodymium, dysprosium, and terbium, which are primarily used in high-performance permanent magnets, showcasing its strategic positioning in critical minerals.
- Transaction Arrangement: Rare Earths Americas will trade on the NYSE American under the symbol REA, with Cantor Fitzgerald and Stifel acting as joint bookrunners for the deal, further enhancing its market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REA
Wall Street analysts forecast REA stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 21.000
Low
Averages
High
Current: 21.000
Low
Averages
High
No data
About REA
Rare Earths Americas, Inc. is an exploration stage company advancing a portfolio of critical minerals projects focused on high-grade heavy rare earth mineral assets. Its portfolio includes three material projects, including Shiloh Project, Alpha Project, and Constellation Project. Shiloh Project is located 110 kilometers (km) south-west from Atlanta, Georgia, United States of America. Alpha Project is a high-grade Brazilian Ionic Clay (IAC) project located in Bahia, Brazil. Alpha Project consists of 36 licenses, and 496 square kilometers of tenements. Constellation Project is Located in the Pocos de Caldas region of Minas Gerais, Brazil. The Constellation Project spans 59.5 square kilometers of tenements. It also Control 1,233 square kilometers of tenements, covering a large and highly prospective niobium district. Its Homer Project is located 180 km from Goiania and 975 km from Santos Port and is close to a paved highway.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rare Earths Americas Raises $63 Million in IPO at High End of Range
- Successful Fundraising: Rare Earths Americas raised $63 million by offering 3.3 million shares at $19 each, achieving the high end of the $17 to $19 range, indicating strong market confidence in its rare earth projects.
- Market Valuation Increase: The pricing gives the company a fully diluted market value of $399 million, an 8% increase from original terms, reflecting investor recognition of ongoing demand for rare earth resources and the company's future potential.
- Project Portfolio Overview: The company has three key projects in the US and Brazil focused on heavy rare earth elements such as neodymium-praseodymium, dysprosium, and terbium, which are primarily used in high-performance permanent magnets, showcasing its strategic positioning in critical minerals.
- Transaction Arrangement: Rare Earths Americas will trade on the NYSE American under the symbol REA, with Cantor Fitzgerald and Stifel acting as joint bookrunners for the deal, further enhancing its market presence.
See More
RARE EARTHS AMERICAS SETS IPO PRICE FOR 3,333,331 SHARES AT $19.00 EACH
Company Overview: Rare Earths Americas has a significant number of shares, totaling 3,333,331.
Stock Price: The current price per share is set at $19.00.
See More
RARE EARTHS AMERICAS: REVEALS PRICING FOR INCREASED INITIAL PUBLIC OFFERING
Company Announcement: Rare Earths America has announced the pricing of its upsized initial public offering (IPO).
IPO Details: The offering is expected to raise significant capital, reflecting strong investor interest in the company's operations.
See More
Five IPOs Scheduled This Week with Significant Capital Raises
- HawkEye 360 IPO: HawkEye 360 plans to raise $400 million at a $2.7 billion market cap, focusing on collecting and processing radio frequency data through small satellites, which, despite being unprofitable, has significant applications in defense and intelligence sectors.
- Odyssey Therapeutics Plans: Odyssey Therapeutics aims to raise $225 million at an $845 million market cap, concentrating on developing targeted therapies for autoimmune and inflammatory diseases, with its lead drug showing early clinical efficacy in ulcerative colitis, indicating strong market potential.
- Suja Life Fundraising: Suja Life intends to raise $200 million at an $871 million market cap, leading in cold-pressed juices and wellness drinks; however, its heavy debt load and interest expenses are pressuring profitability despite strong vertical integration supporting processing cycles.
- Mobia Medical Innovation: Mobia Medical plans to raise $150 million at a $549 million market cap, with its FDA-approved nerve stimulation device providing clinically validated solutions for moderate to severe ischemic stroke patients, showcasing significant market application value.
See More
Rare Earths Americas Raises $63 Million in IPO at High End of Range
- Successful Fundraising: Rare Earths Americas raised $63 million by offering 3.3 million shares at $19 each, achieving the high end of the $17 to $19 range, indicating strong market confidence in its rare earth projects.
- Market Valuation Increase: The pricing gives the company a fully diluted market value of $399 million, an 8% increase from original terms, reflecting investor recognition of ongoing demand for rare earth resources and the company's future potential.
- Project Portfolio Overview: The company has three key projects in the US and Brazil focused on heavy rare earth elements such as neodymium-praseodymium, dysprosium, and terbium, which are primarily used in high-performance permanent magnets, showcasing its strategic positioning in critical minerals.
- Transaction Arrangement: Rare Earths Americas will trade on the NYSE American under the symbol REA, with Cantor Fitzgerald and Stifel acting as joint bookrunners for the deal, further enhancing its market presence.
See More
RARE EARTHS AMERICAS SETS IPO PRICE FOR 3,333,331 SHARES AT $19.00 EACH
Company Overview: Rare Earths Americas has a significant number of shares, totaling 3,333,331.
Stock Price: The current price per share is set at $19.00.
See More
RARE EARTHS AMERICAS: REVEALS PRICING FOR INCREASED INITIAL PUBLIC OFFERING
Company Announcement: Rare Earths America has announced the pricing of its upsized initial public offering (IPO).
IPO Details: The offering is expected to raise significant capital, reflecting strong investor interest in the company's operations.
See More
Five IPOs Scheduled This Week with Significant Capital Raises
- HawkEye 360 IPO: HawkEye 360 plans to raise $400 million at a $2.7 billion market cap, focusing on collecting and processing radio frequency data through small satellites, which, despite being unprofitable, has significant applications in defense and intelligence sectors.
- Odyssey Therapeutics Plans: Odyssey Therapeutics aims to raise $225 million at an $845 million market cap, concentrating on developing targeted therapies for autoimmune and inflammatory diseases, with its lead drug showing early clinical efficacy in ulcerative colitis, indicating strong market potential.
- Suja Life Fundraising: Suja Life intends to raise $200 million at an $871 million market cap, leading in cold-pressed juices and wellness drinks; however, its heavy debt load and interest expenses are pressuring profitability despite strong vertical integration supporting processing cycles.
- Mobia Medical Innovation: Mobia Medical plans to raise $150 million at a $549 million market cap, with its FDA-approved nerve stimulation device providing clinically validated solutions for moderate to severe ischemic stroke patients, showcasing significant market application value.
See More
